Takeda to Cut 137 Staffers After Exiting Cell Therapy Research
Takeda; layoffs; cell therapy exit; biotech industry; restructuring; Massachusetts R&D; strategic portfolio reprioritization; pipeline shake-up
Cirrus Therapeutics Raises $11M to Advance Gene Therapy Targeting Dry Age-Related Macular Degeneration
Cirrus Therapeutics; gene therapy; dry AMD; IRAK-M; AAV; seed funding; ocular immunology; vision loss
Despite Government Shutdown, Companies Still Plan to Submit FDA Applications
FDA shutdown; new drug applications; biologic applications; user fees; pharmaceutical delays; government funding lapse; AbbVie; Amgen; Bristol Myers Squibb; J&J; Pfizer
Behind-the-Scenes Details of 89bio’s $2.4B Deal with Roche
Roche; 89bio; pegozafermin; MASH; liver disease; contingent value rights; biotech acquisition; pharmaceuticals; deal structure; milestone payments
Vanda Ends Lawsuits Against FDA in Broad Settlement, Paving Way for Drug Review Progress
Vanda Pharmaceuticals; FDA; Hetlioz; jet lag disorder; tradipitant; lawsuit dismissal; collaborative framework; clinical trial hold; drug approval; sNDA; motion sickness
Amgen’s Repatha Cholesterol-Lowering Shot Poised for Sales Boost After Landmark CV Prevention Trial Success
Amgen; Repatha; cholesterol-lowering; PCSK9 inhibitor; cardiovascular trial; VESALIUS-CV; primary prevention; heart disease; sales; LDL cholesterol
Trump Administration and Pfizer Strike ‘Most Favored Nation’ Drug Price Deal
Trump; Pfizer; most favored nation; drug prices; Medicaid; TrumpRx; direct-to-consumer; pharmaceutical industry; PhRMA; AmericasMedicines.com
Ansa Biotechnologies Raises $54.4M in Series B to Scale US DNA Synthesis Manufacturing
Ansa Biotechnologies; Series B financing; DNA synthesis; Cerberus Ventures; US manufacturing; biotechnology; synthetic DNA; fundraising
Fortress Biotech and Sentynl Therapeutics Fail to Secure FDA Approval for CUTX-101 in Rare Pediatric Menkes Disease
Fortress Biotech; Sentynl Therapeutics; FDA Complete Response Letter; CUTX-101; Menkes disease; rare pediatric disease; manufacturing deficiencies; drug approval setback
Aerska Launches with $21M to Use Brain ‘Shuttles’ for RNAi Delivery in Neurological Diseases
Aerska; Irish biotech; RNA interference (RNAi); brain shuttles; blood-brain barrier; neurological diseases; Alzheimer’s; Parkinson’s; gene silencing; precision medicine; antibody-oligonucleotide conjugates